MA-IMMUTA
8.6.2022 14:00:09 CEST | Business Wire | Press release
Immuta , the leader in data access and data security, today announced that it has secured $100 million in Series E funding. With this investment, Immuta will meet growing data security and privacy demands by accelerating secure data access across all cloud platforms. Only Immuta can automate access to data by discovering, securing, and monitoring data on any cloud service. The new investment brings Immuta’s total financing to date to $267 million.
Led by NightDragon , the funding round also includes new investor Snowflake Ventures , the venture capital arm of the Data Cloud company, as well as participation from existing investors Dell Technologies Capital, DFJ Growth, IAG, Intel Capital, March Capital, StepStone, Ten Eleven Ventures, and Wipro Ventures. This new infusion of capital builds upon Immuta’s record growth in 2021 , which included increasing commercial annual recurring revenue (ARR) by more than 100 percent, doubling its customer base, and continuing its global expansion into EMEA and APJ. Immuta will use the investment to accelerate product innovation, expand sales, marketing, and customer success teams to meet growing global demand, and deepen strategic partnerships within the cloud data ecosystem.
“There is a major shift in the modern data stack as organizations scale to derive value from their data more quickly, while also protecting their data assets and adhering to privacy regulations,” said Immuta CEO Matthew Carroll. “We’ve entered the next wave of the cloud data evolution where automation and security are essential to meeting modern cloud and data demands. This new funding will help propel Immuta into our next phase of growth as we continue to revolutionize cloud data access and data security.”
“As the threat landscape continues to escalate and cloud migration continues, we’re seeing increased global interest in the need for secure data access solutions,” said Dave DeWalt, former CEO of FireEye, McAfee, Documentum and now Founder and Managing Director at NightDragon. “Immuta is the clear market leader in providing secure data access, providing data teams with one universal platform to control access to data at scale. Many of the world’s top data-driven organizations – Roche, Mercedes-Benz Group, IAG, and the U.S. Army – rely on Immuta every day to quickly, safely, and efficiently share more data with more users. We’re excited to be making this investment in such a critical part of the modern data stack.”
As the market leader in data access and data security, Immuta enables organizations to discover, protect, and monitor sensitive data so that users can access it – as long as they have the rights. From startups to global enterprises, organizations are struggling to provide access to data at scale while ensuring it’s done securely and in accordance with local rules and privacy regulations. Immuta offers customers the ability to secure their data in the cloud at a more granular level and easily enforce data security policies. Immuta is rapidly expanding to address these demands, and recently announced its expansion into the Australian and New Zealand markets with the addition of new customers and new hires in the region. In 2021, Immuta further expanded its partner network of top cloud data platforms with native integrations to include Snowflake , Databricks , Amazon , Google , Azure , and Starburst .
“With this expanded partnership, enterprise customers can benefit from both Snowflake’s native data policies for data governance and Immuta’s simple, centralized, and comprehensive method for managing and automating data policy within specific workflows,” said Christian Kleinerman, Snowflake SVP of Product. “Together, customers have a solution for more seamless enforcement of data policy, ultimately allowing for more customer value. We look forward to partnering with Immuta through the next stages of its growth.”
For more information about Immuta, visit www.immuta.com . Join the Immuta conversation on LinkedIn and Twitter .
About Immuta
Immuta is the market leader in secure Data Access, providing data teams one universal platform to control access to analytical data sets in the cloud. Only Immuta can automate access to data by discovering, protecting, and monitoring data. Data-driven organizations around the world trust Immuta to speed time to data, safely share more data with more users, and mitigate the risk of data leaks and breaches. Founded in 2015, Immuta is headquartered in Boston, MA. To learn more about Immuta careers, click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608005624/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
